Back to Wyoming

SF0151 • 2023

Wyoming prescription drug transparency act.

AN ACT relating to the insurance code; prohibiting specified actions by pharmacy benefit managers; allowing individuals to choose in network retail pharmacies as specified; providing definitions; excluding certain claims as specified; amending a definition; requiring pharmacy benefit managers to provide contact information as specified; amending the process for when a maximum allowable cost appeal is denied; requiring pharmacy benefit managers to allow pharmacies to file appeals in electronic batch formats; requiring pharmacy benefit managers to reimburse pharmacies as specified; authorizing pharmacies to decline to provide pharmacy services as specified; making conforming amendments; requiring rulemaking; providing appropriations; and providing for effective dates.

Budget Children Healthcare Labor Taxes
Enacted

This bill passed the Legislature and reached final enactment based on the latest official action.

Sponsor
Senator Hutchings
Last action
2023-03-17
Official status
enrolled
Effective date
7/1/2023

Plain English Breakdown

The act's impact on insurance companies and individuals is implied but not explicitly stated in the summary.

Wyoming Prescription Drug Transparency Act

This act sets rules for how pharmacy benefit managers must operate in Wyoming, including prohibiting certain actions and requiring clear contact information.

What This Bill Does

  • Prohibits pharmacy benefit managers from retroactively denying or reducing reimbursement after a claim has been processed unless it is due to fraud or an audit error.
  • Requires contracts between pharmacy benefit managers and pharmacies to include processes for investigating disputes and resolving them through appeals.
  • Requires pharmacy benefit managers to provide contact information so pharmacies can discuss appeals.
  • Allows pharmacies to file appeals in electronic batch formats.

Who It Names or Affects

  • Pharmacy benefit managers
  • Retail pharmacies

Terms To Know

pharmacy acquisition cost
The price a pharmacy pays for drugs from wholesalers.
spread pricing
A model where the price charged to insurance plans differs from what is paid to pharmacies.

Limits and Unknowns

  • Does not apply to certain government programs like Medicaid.
  • The act does not specify all details of how appeals should be handled, leaving some room for interpretation.

Amendments

These notes stay tied to the official amendment files and metadata from the legislature.

SF0151H2001

2nd reading • Representative Zwonitzer, Dn

Adopted

Plain English: The amendment removes specific sections from the bill that deal with pharmacy benefit manager actions and requirements.

  • Removes a section related to certain actions by pharmacy benefit managers.
  • Eliminates provisions about how pharmacies can file appeals in electronic batch formats.
  • Deletes rules concerning when pharmacy benefit managers must reimburse pharmacies.
  • The exact nature and impact of the removed sections are not detailed, making it hard to explain their specific effects fully.
SF0151H2002

2nd reading • Representative Strock

Corrected, Adopted

Plain English: The amendment excludes certain claims from the provisions of Wyoming's prescription drug transparency act, specifically those related to Medicaid fee-for-service program, workers compensation division, and federal law prohibitions.

  • Adds a new section (26-52-107) that excludes specific types of claims from being covered by certain sections of the bill.
  • Modifies references in the bill text to include an additional section number.
  • The amendment does not provide detailed information on how these exclusions will be implemented or enforced, leaving some aspects unclear.
SF0151H2003

2nd reading • Representative Zwonitzer, Dn

Corrected, Adopted

Plain English: The amendment updates the definition of 'specialty medication' to include specific criteria such as high cost, rare medical conditions, limited distribution, and specialized handling requirements.

  • Adds a new definition for 'Specialty Medication', which includes prescription drugs that are typically expensive and meet certain criteria like being prescribed for chronic or rare conditions, having limited distribution, requiring special handling by the pharmacy, or needing intensive clinical care.
  • The amendment only provides an updated definition and does not specify how this new term will be used in other parts of the bill.
SF0151H2004

2nd reading • Representative Zwonitzer, Dn

Corrected, Failed

Plain English: The amendment changes the wording in a bill about pharmacy benefit managers to specify that certain actions apply only to brand drugs and not generic ones, and it also removes some requirements for pharmacies.

  • Changes 'prescription' to 'generic' on page 4, line 2, so that pricing restrictions without consent of the health plan now apply specifically to brand drugs rather than all prescriptions.
  • Removes language requiring pharmacy benefit managers from requesting information from pharmacies on page 5, line 1.
  • Deletes requirements for sharing or transmitting data by pharmacy benefit managers starting at page 5, line 23.
  • The amendment text does not provide full context about the impact of these changes on other parts of the bill.
SF0151H2005

2nd reading • Representative Zwonitzer, Dn

Corrected, Adopted

Plain English: The amendment changes the amount of funds allocated for a specific purpose from $95,000 to $125,000 and updates where these funds are deposited.

  • Changes the funding amount from $95,000 to $125,000.
  • Updates the fund designation from 'special revenue funds' to 'the general fund'.
  • Modifies dates related to appropriations from 2024 to 2025.
  • The exact purpose of these funding changes is not detailed in the amendment text provided.
SF0151H2006

2nd reading • Representative Zwonitzer, Dn

Divided

Plain English: The amendment removes specific language related to brand pricing from the bill.

  • Removes lines 11 through 18 on page 5 of the bill.
  • Deletes 'brand and' after line 17 on page 6.
  • Eliminates lines 19 and 20 on page 6.
  • The exact impact of removing this language is not fully explained in the amendment text.
SF0151H2006.01

2nd reading • Representative Zwonitzer, Dn

Corrected, Adopted

Plain English: The amendment removes specific wording related to brand pricing from the bill.

  • Removes 'brand and' after 'pricing' on page 6, line 17 of the bill.
  • The exact impact of removing this phrase is unclear without additional context about how it was originally intended to be used in the bill.
SF0151H2006.02

2nd reading • Representative Zwonitzer, Dn

Corrected, Failed

Plain English: The amendment removes specific lines from the bill that deal with pharmacy benefit managers' actions.

  • Removes certain provisions related to pharmacy benefit managers' responsibilities.
  • The exact details of what was removed are not provided, making it unclear what specific changes this amendment would make to the original bill.
SF0151H3001

3rd reading • Representative Penn

Adopted

Plain English: The amendment removes specific language from the bill regarding pharmacy benefit managers.

  • Removes a section of text on page 6, line 19 of the bill.
  • It is unclear what exact content was removed and its impact without seeing the original text.
SF0151H3002

3rd reading • Representative Zwonitzer, Dn

Failed

Plain English: The amendment changes the bill to require pharmacy benefit managers to get permission from health benefit plans before changing pricing and removes certain language about services.

  • Adds a requirement that pharmacy benefit managers must have consent from health benefit plans before making any pricing changes.
  • Removes specific wording related to services provided by pharmacies.
  • The amendment text does not provide full details on what exact language is being removed or the implications of these changes, which limits a complete understanding of its impact.
SF0151HW001

Committee of the Whole • Representative Zwonitzer, Dn

Corrected, Withdrawn

Plain English: The amendment removes certain provisions from the bill and adds a new definition related to maximum allowable cost lists.

  • Removes specific amendments made by the House standing committee that were previously added to the bill.
  • Adds a new definition for 'maximum allowable cost list' which is an electronic, searchable list of drugs with established costs used for generic medicine reimbursement.
  • Modifies language related to pharmacy benefit manager regulations and their applicability.
  • The amendment text does not provide full context or details about the removed provisions, making it difficult to understand all implications.
SF0151HW002

Committee of the Whole • Representative Strock

Withdrawn

Plain English: The amendment removes certain entities from the definition of 'pharmacy benefit manager' and makes other minor changes to the bill.

  • Excludes entities that contract with Wyoming Workers’ Compensation Division or work with federal health programs like Medicare and Medicaid from being considered pharmacy benefit managers under this act.
  • Removes a comma on page 10, line 3 of the bill.
  • Deletes lines 4 and 5 on page 10 of the bill.
  • The exact content removed by deleting lines 4 and 5 is not specified in the amendment text.
SF0151HW003

Committee of the Whole • Representative Locke

Withdrawn

Plain English: The amendment removes specific sections and language from the bill related to pharmacy benefit managers.

  • Removes a section of text on page 7, lines 2 and 11-22.
  • Removes another section of text on page 8, lines 1-9.
  • The exact content removed is not provided in the amendment text, making it hard to explain what specific changes are being made beyond noting sections have been deleted.
SF0151HW004

Committee of the Whole • Representative Strock

Withdrawn

Plain English: The amendment changes the definition of 'specialty medication' in the bill to include specific criteria such as high cost, rare medical conditions, and specialized handling requirements.

  • Adds a new definition for 'specialty medication', which includes prescription drugs that are typically expensive and meet certain criteria like being prescribed for chronic or rare conditions, having limited distribution, or requiring special handling by the pharmacy.
  • The amendment only provides part of the definition for specialty medications and does not explain how this change will affect other parts of the bill.
SF0151HW005

Committee of the Whole • Representative Strock

Withdrawn

Plain English: The amendment modifies the bill by excluding certain claims from specific sections of Wyoming's insurance code, changing references to other parts of the law, and making minor textual adjustments.

  • Adds a new section (26-52-107) that excludes claims related to the Wyoming Medicaid fee-for-service program, the Wyoming workers compensation division, or those prohibited by federal law from applying to certain sections of the insurance code.
  • Updates references in the bill text to include an additional section number (through 26-52-107).
  • Removes a comma and two lines of text that are no longer needed.
  • The amendment's full impact on existing claims processes is not fully explained in the provided text.
  • It is unclear how this exclusion will affect the overall implementation of the bill's provisions.
SF0151HS001

Standing Committee • House Revenue Committee

Failed

Plain English: The amendment removes several provisions from the original bill related to pharmacy benefit managers, including sections about appeals processes, electronic batch formats for filing disputes, and specific definitions.

  • Removes language allowing individuals to choose in-network retail pharmacies under certain conditions.
  • Eliminates provisions requiring pharmacy benefit managers to provide contact information and allow pharmacies to file appeals in electronic batch formats.
  • Deletes sections detailing the process when a maximum allowable cost appeal is denied, as well as specific definitions related to pharmacy benefits.
  • The amendment text does not explain all removed provisions clearly, making it hard to understand every detail of what was deleted.
SF0151SW001

Committee of the Whole • Senator Hutchings

Corrected, Adopted

Plain English: The amendment modifies the Wyoming prescription drug transparency act by excluding specialty medications from certain provisions, requiring pharmacy benefit managers to remit retained funds to insurers for premium reduction or direct remittance to covered persons, and adding new requirements for contract dispute resolution processes.

  • Excludes specialty medications from specific provisions related to in-network retail pharmacies and reimbursement methodologies.
  • Requires pharmacy benefit managers to remit retained funds from pharmaceutical manufacturer negotiations to insurers for lowering premiums or reducing out-of-pocket costs for covered individuals.
  • Adds new requirements for contracts between pharmacy benefit managers, pharmacy services administrative organizations, and pharmacies regarding dispute resolution processes.
  • The amendment text does not provide specific details on how the exclusion of specialty medications will be implemented in practice.

Bill History

  1. 2023-03-17 LSO

    Assigned Chapter Number 189

  2. 2023-03-17 Governor

    Governor Signed SEA No. 0090

  3. 2023-03-17 Wyoming Legislature

    Veto Message Received

  4. 2023-03-17 Governor

    Governor Vetoed SEA No. 0090

  5. 2023-03-02 House

    H Speaker Signed SEA No. 0090

  6. 2023-03-02 Senate

    S President Signed SEA No. 0090

  7. 2023-03-02 LSO

    Assigned Number SEA No. 0090

  8. 2023-03-02 Senate

    S Concur:Passed 19-11-1-0-0

  9. 2023-03-01 Senate

    S Received for Concurrence

  10. 2023-03-01 House

    H 3rd Reading:Passed 40-21-1-0-0

  11. 2023-02-28 House

    H 2nd Reading:Passed

  12. 2023-02-27 House

    H 2nd Reading:Laid Back

  13. 2023-02-24 House

    H COW:Passed

  14. 2023-02-22 House

    H Placed on General File

  15. 2023-02-22 House

    H02 - Appropriations:Do Pass Failed 4-3-0-0-0

  16. 2023-02-22 House

    :Rerefer to H02 - Appropriations

  17. 2023-02-22 House

    H03 - Revenue:Recommend Amend and Do Pass 9-0-0-0-0

  18. 2023-02-14 House

    H Introduced and Referred to H03 - Revenue

  19. 2023-02-08 House

    H Received for Introduction

  20. 2023-02-08 Senate

    S 3rd Reading:Passed 23-8-0-0-0

  21. 2023-02-07 Senate

    S 2nd Reading:Passed

  22. 2023-02-06 Senate

    S COW:Passed

  23. 2023-02-02 Senate

    S Placed on General File

  24. 2023-02-02 Senate

    S02 - Appropriations:Recommend Do Pass 4-1-0-0-0

  25. 2023-02-01 Senate

    :Rerefer to S02 - Appropriations

  26. 2023-02-01 Senate

    S10 - Labor:Recommend Do Pass 3-2-0-0-0

  27. 2023-01-24 Senate

    S Introduced and Referred to S10 - Labor

  28. 2023-01-24 Senate

    S Received for Introduction

  29. 2023-01-21 LSO

    Bill Number Assigned

Official Summary Text

Bill Summary - 23LSO-0430
Bill No.:

SF0151

Effective:

Multiple Dates

LSO No.:

23LSO-0430

Enrolled Act No.:

SEA No. 0090

Chapter No.:

189

Prime Sponsor:

Hutchings

Catch Title:

Wyoming prescription drug transparency act.

Subject:

Amends pharmacy benefit manager practices.

Summary/Major Elements:

This act prohibits certain actions by pharmacy benefit managers, including in part retroactively denying or reducing reimbursement for a covered pharmacy service or claim.

This act requires all contracts between a pharmacy benefit manager and a pharmacy services administrative organization or a pharmacy to include a process to investigate and resolve disputes.

This act requires pharmacy benefit managers to provide reliable contact information to pharmacies for purposes of discussing appeals and also authorizes network pharmacies to file appeals in electronic batch formats.

This act also authorizes pharmacies to decline to provide pharmacy services if the pharmacy or pharmacist is to be paid less than the pharmacy acquisition cost for the pharmacy providing pharmacy services.

This act authorizes one position to the Department of Insurance and appropriates one hundred twenty-five thousand dollars ($125,000.00) for the salary and benefits of the position. It also appropriates one hundred thousand dollars ($100,000.00) from the general fund to the Department of Insurance to implement this act.

The above summary is not an official publication of the Wyoming Legislature and is not an official statement of legislative intent.

While the Legislative Service Office endeavored to provide accurate information in this summary, it should not be relied upon as a comprehensive abstract of the bill.

Current Bill Text

Read the full stored bill text
23LSO-0430

ORIGINAL Senate

ENGROSSED
File No
.
SF0151

ENROLLED ACT NO. 90,

SENATE

SIXTY-SEVENTH LEGISLATURE OF THE STATE OF WYOMING
2023 General Session

AN ACT relating to the insurance code; prohibiting specified actions by pharmacy benefit managers; allowing individuals to choose in network retail pharmacies as specified; providing definitions; excluding certain claims as specified; amending a definition; requiring pharmacy benefit managers to provide contact information as specified; amending the process for when a maximum allowable cost appeal is denied; requiring pharmacy benefit managers to allow pharmacies to file appeals in electronic batch formats; requiring pharmacy benefit managers to reimburse pharmacies as specified; authorizing pharmacies to decline to provide pharmacy services as specified; making conforming amendments; requiring rulemaking; providing appropriations; and providing for effective dates.

Be It Enacted by the Legislature of the State of Wyoming:

Section 1
.

W.S. 26
‑
52
‑
105 through 26
‑
52
‑
107 are created to read:

26
‑
52
‑
105.

Transparency; prohibitions.

(a)

A pharmacy benefit manager or an agent of a pharmacy benefit manager shall not:

(i)

Cause or knowingly permit the use of an advertisement, promotion, solicitation, representation, proposal or offer that is untrue, deceptive or misleading;

(ii)

Charge

a pharmacist or pharmacy provider a fee for any of the following:

(A)

The submission of a claim;

(B)

Enrollment or participation in a retail pharmacy network;

(C)

The development or management of claims processing services or claims payment services related to participation in a retail pharmacy network;

(D)

An application to apply for network access with the pharmacy benefit manager;

(E)

Credentialing or re
‑
credentialing;

(F)

Any change of ownership.

(iii)

Retroactively deny or reduce reimbursement for a covered pharmacy service or claim after adjudication of the claim, unless:

(A)

The original claim was fraudulent; or

(B)

The denial or reduction is necessary to correct errors found in an audit, provided that the audit was conducted in compliance with W.S. 26
‑
52
‑
103.

(iv)

Restrict a person's choice of network providers for prescription drugs, except for specialty medications as defined by W.S. 26
‑
52
‑
102(a)(xi);

(v)

Conduct spread pricing;

(vi)

Retain funds paid by a pharmaceutical manufacturer to a pharmacy benefits manager as a result of negotiations of a reduced price for a pharmaceutical between a pharmacy benefits manager and a manufacturer, in relation to a contract between a pharmacy benefits manager and an insurer related to its insured prescription drug benefits. Funds retained under this paragraph shall be remitted to and retained by the insurer and shall be used by the insurer to lower premiums for covered persons under the insurer's health benefits plan or to allow for remittance directly to the covered person at the point of sale to reduce the covered person's out
‑
of
‑
pocket costs;

(vii)

Prohibit a pharmacy, pharmacy services administrative organization, contracting agent or agent of a pharmacy from sharing, upon request, copies of pharmacy benefit manager contracts with requesting pharmacies or the department of insurance;

(viii)

Prohibit, restrict or limit disclosure of information to the insurance commissioner, law enforcement or other state or federal government officials who are investigating or examining a complaint or conducting a review of the pharmacy benefit manager's compliance with the requirements of this chapter;

(ix)

Reimburse a pharmacy for pharmacy services in an amount less than the amount that the pharmacy benefit manager reimburses a pharmacy benefit manager owned or pharmacy benefit manager affiliated pharmacy for providing the same pharmacy services. The reimbursement amount paid to the pharmacy shall be equal to the reimbursement amount paid to a pharmacy benefit manager owned or pharmacy benefit manager affiliated pharmacy.

(b)

A person's choice of network provider shall include a retail pharmacy. An insurer or pharmacy benefit manager shall not require or incentivize using any discounts in cost sharing or a reduction in copay or the number of copays to individuals to receive prescription drugs from an individual's choice of in network pharmacy, except for specialty medications as defined by W.S. 26
‑
52
‑
102(a)(xi).

(c)

Insurers, pharmacies and pharmacy benefit managers shall adhere to all state laws and rules when mailing or shipping prescription drugs into the state.

26
‑
52
‑
106.

Alternate reimbursement methodologies.

(a)

All contracts between a pharmacy benefits manager and a pharmacy services administrative organization, or its contracted pharmacies, and all contracts directly between a pharmacy benefits manager and a pharmacy shall include a process to investigate and resolve disputes and allow appeals regarding brand and multiple
‑
source generic drug pricing, including if applicable brand effective rates, for pharmacy reimbursement.

(b)

Appeals authorized under this section shall comply with the procedures specified in W.S. 26
‑
52
‑
104.

26
‑
52
‑
107.

Certain claims excluded.

W.S. 26
‑
52
‑
104 through 26
‑
52
‑
106 shall apply to all health benefit plan issuers and pharmacy benefit managers except those claims associated with the Wyoming Medicaid fee
‑
for
‑
service program, the Wyoming workers compensation division or those claims otherwise prohibited by federal law.

Section 2.

W.S. 26
‑
52
‑
102(a)(vii) and by creating new paragraphs (viii) through (xii) and 26
‑
52
‑
104(a)(i), (d)(ii), (e), (f) and by creating new subsections (k) and (m) are amended to read:

26
‑
52
‑
102.

Definitions.

(a)

As used in this article:

(vii)

"Pharmacy benefit manager" means an entity that contracts with a pharmacy
or the pharmacy's designee who holds a contract with the pharmacy benefit manager
on behalf of an insurer or third party administrator to administer or manage prescription drug benefits
;
.

(viii)

"Pharmacy acquisition cost" means the amount a pharmaceutical wholesaler charges for a pharmaceutical product as listed on the pharmacy's billing invoice;

(ix)

"Pharmacy services" means any product, good or service, or any combination of products, goods or services, provided as part of the practice of pharmacy;

(x)

"Pharmacy services administrative organization" means an organization that evaluates and executes pharmacy benefit manager contracts on behalf of pharmacies and provides administrative, clerical, audit and data analytics support services;

(xi)

"Specialty medication" means a prescription drug that is typically high cost and that:

(A)

Is prescribed for a person with a:

(I)

Chronic, complex or life
‑
threatening condition; or

(II)

Rare medical condition.

(B)

Has limited or exclusive distribution; or

(C)

Requires:

(I)

Specialized product handling or administration by the dispensing pharmacy; or

(II)

Specialized clinical care, including frequent dosing adjustments, intensive clinical monitoring or expanded services for patients.

(xii)

"Spread pricing" means a prescription drug pricing model utilized by a pharmacy benefit manager where the pharmacy benefit manager charges a health benefit plan a contracted price for prescription drugs that differs from the amount the pharmacy benefit manager directly or indirectly pays the pharmacy or pharmacist for providing prescription drugs.

26
‑
52
‑
104.

Maximum allowable cost; offering information and alternatives.

(a)

To place a drug on a maximum allowable cost list, a pharmacy benefit manager shall ensure that the drug is:

(i)

If the drug is a generically equivalent drug, r
ated "A" or "B" in the most recent version of the United States Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), or rated "NR" or "NA," or has a similar rating, by a nationally recognized reference;

(d)

A pharmacy benefit manager shall:

(ii)

Provide a telephone number
, email address and website
at which a network pharmacy
or the pharmacy's designee who holds a contract with the pharmacy benefit manager
may contact an employee of a pharmacy benefit manager to discuss the pharmacy's appeal;

(e)

A pharmacy benefit manager shall establish a process by which a contracted pharmacy, or the pharmacy's designee who holds a contract with the pharmacy benefit manager, can appeal the provider's reimbursement for a drug subject to maximum allowable cost pricing. A contracted pharmacy, or the pharmacy's designee who holds a contract with the pharmacy benefit manager, shall have up to ten (10) business days after dispensing a drug subject to a maximum allowable cost in which to appeal the amount of the maximum allowable cost. A pharmacy benefit manager shall respond to the appeal within ten (10) business days after the contracted pharmacy
or the pharmacy's designee who holds a contract with the pharmacy benefit manager
makes the appeal.

(f)

If a maximum allowable cost appeal is denied, the pharmacy benefit manager shall provide to the appealing pharmacy, or the pharmacy's designee who holds a contract with the pharmacy benefit manager, the reason for the denial and the national drug code number for the drug that is available for purchase by
similarly situated
pharmacies in the state
from
and the names of
national or regional wholesalers
that have the product available for purchase
at a price
that is
at or below the maximum allowable cost.

(k)

A pharmacy benefit manager shall not prevent a network pharmacy or the pharmacy's designee who holds a contract with the pharmacy benefit manager from filing appeals in an electronic batch format. The pharmacy benefit manager shall respond in an electronic format to valid reimbursement appeals filed in an electronic batch format. A batch appeal shall not be considered a valid appeal unless all required information for each claim in the batch is submitted electronically with the correct, contractually required information and in the required format. An appeal shall not be considered valid for purposes of the ten (10) day response timeframe until all information is received.

(m)

A pharmacy or pharmacist may decline to provide pharmacy services to a patient or pharmacy benefit manager if the pharmacy or pharmacist is to be paid less than the pharmacy acquisition cost for the pharmacy providing pharmacy services.

Section 3.

(a)

The department of insurance is authorized one (1) full
‑
time position for the purpose of implementing and administering this act. There is appropriated one hundred twenty
‑
five thousand dollars ($125,000.00) from the general fund to the department of insurance for the salary and benefits of the position authorized under this section. This appropriation shall be for the period beginning with the effective date of this section and ending June 30, 2024 and shall only be expended for the additional position authorized under this section. This appropriation shall not be transferred or expended for any other purpose and any unexpended, unobligated funds remaining from this appropriation shall revert as provided by law on June 30, 2024.

(b)

There is appropriated one hundred thousand dollars ($100,000.00) from the general fund to the department of insurance for the purposes of implementing and administering this act. This appropriation shall be for the period beginning with the effective date of this section and ending June 30, 2025. This appropriation shall not be transferred or expended for any other purpose and any unexpended, unobligated funds remaining from this appropriation shall revert as provided by law on June 30, 2025.

Section 4.

The department of insurance shall promulgate any rules necessary to implement this act.

Section 5.

(a)

Except as otherwise provided by subsection (b) of this section, this act is effective July 1, 2023.

(b)

Sections 3, 4 and 5 of this act are effective immediately upon completion of all acts necessary for a bill to become law as provided by Article 4, Section 8 of the Wyoming Constitution.

(END)

Speaker of the House

President of the Senate

Governor

TIME APPROVED: _________

DATE APPROVED: _________

I hereby certify that this act originated in the Senate.

Chief Clerk

1